Ewing Sarcoma (ES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Ewing Sarcoma (ES) Market Outlook

Thelansis’s “Ewing Sarcoma (ES) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ewing Sarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ewing Sarcoma (ES) Overview

Ewing sarcoma (ES), a peripheral primitive neuroectodermal tumor, is a malignancy originating from a specific cell type in either bone or soft tissue. This tumor condition is characterized by chromosomal rearrangements involving the long arms (q) of chromosomes 11 and 22 (11q24-22q12), resulting in the abnormal fusion of two genes, typically EWS and FLI. The standard approach to treating ES, whether it has metastasized or not, involves a multidisciplinary approach that includes chemotherapy and local therapies such as surgery and radiotherapy (RT). Complications associated with Ewing sarcoma may include metastasis, local recurrence, secondary cancers, pathological fractures, and morbidities associated with surgery, radiation, and chemotherapy. Ewing sarcoma primarily affects adolescents and young adults, with a median age of onset at 15 years. It accounts for less than 5% of all soft tissue sarcomas. The highest incidence occurs between the ages of 10 and 15, with approximately 30% of cases diagnosed in children under 10 and another 30% in adults over 20. There is a notable male predominance, with a male-to-female ratio of 3 to 1.

• The annual incidence of Ewing sarcoma is approximately 2.93 cases per 100,000 children.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: